- Home
- / Brainstorm Cell Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Brainstorm Cell Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2
2024-10-29
Market Capitalization
$10.8 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 2.2M | 1.7M | 2.1M | 2.6M | 3.6M | 2.8M | 4.0M | 5.8M | 5.8M | 9.4M | 9.3M | 10.9M | 10.7M | 7.0M | 5.8M |
| Operating expense total | 3.9M | 3.5M | 5.0M | 7.4M | 8.5M | 5.1M | 5.0M | 14.1M | 23.0M | 31.7M | 24.8M | 11.7M | 10.0M | ||
| EBIT | 3.9M | (3.4M) | (4.9M) | (7.4M) | (8.5M) | (5.1M) | (5.0M) | (14.1M) | (23.0M) | (31.7M) | (24.5M) | (24.8M) | (21.4M) | (11.7M) | (10.0M) |
| Interest income | 132.0K | 1.8M | |||||||||||||
| Interest expense | 151.0K | 93.0K | 48.0K | ||||||||||||
| Pre tax profit | (3.4M) | (5.0M) | (5.0M) | (13.9M) | (23.3M) | (31.8M) | (24.5M) | (24.3M) | (17.2M) | (11.6M) | (10.3M) | ||||
| Income tax expense | (5.0K) | 5.0K | 25.0K | ||||||||||||
| Net Income | (3.9M) | (3.4M) | (4.9M) | (9.2M) | (8.5M) | (5.0M) | (5.0M) | (13.9M) | (23.3M) | (31.8M) | (24.5M) | (24.3M) | (17.2M) | (11.6M) | (10.3M) |
| EPS | (0.7) | (2.3) | (1.1) |